Tiny trial tracks new Drug's journey in dialysis patients
NCT ID NCT07284043
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-stage study looks at how the experimental drug MT1013 moves through and leaves the body of people on hemodialysis who have secondary hyperparathyroidism. Six participants will receive a single dose, and researchers will measure radioactivity in blood, urine, and stool to track the drug. The goal is not to treat the disease but to understand the drug's breakdown and elimination, which is a necessary step before larger safety and effectiveness trials can begin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MT1013 (a dual-target agonist drug)
- What this could lead to
- If successful, this study will clarify how MT1013 is absorbed and eliminated, which is essential for future dosing and safety studies.
- What could go wrong
- This is a very early Phase 1 trial with only 6 participants, so results may not apply broadly. The drug is still experimental and may not prove effective or safe in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS SUBJECTS WITH SECONDARY HYPERPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
Jinan, Shandong, 250014, China